QQQ   290.27 (-2.02%)
AAPL   143.00 (-2.01%)
MSFT   242.71 (-2.20%)
META   147.06 (-3.08%)
GOOGL   96.94 (-2.45%)
AMZN   100.55 (-1.65%)
TSLA   166.66 (-6.32%)
NVDA   191.62 (-5.91%)
NIO   12.02 (-5.43%)
BABA   111.20 (-6.07%)
AMD   72.45 (-3.91%)
T   20.16 (+1.05%)
MU   61.71 (-3.38%)
F   12.89 (-2.86%)
CGC   2.84 (-3.07%)
GE   80.83 (-2.88%)
DIS   107.59 (-1.78%)
AMC   5.01 (-9.07%)
PFE   43.55 (-0.55%)
PYPL   79.64 (-2.68%)
NFLX   353.11 (-2.12%)
QQQ   290.27 (-2.02%)
AAPL   143.00 (-2.01%)
MSFT   242.71 (-2.20%)
META   147.06 (-3.08%)
GOOGL   96.94 (-2.45%)
AMZN   100.55 (-1.65%)
TSLA   166.66 (-6.32%)
NVDA   191.62 (-5.91%)
NIO   12.02 (-5.43%)
BABA   111.20 (-6.07%)
AMD   72.45 (-3.91%)
T   20.16 (+1.05%)
MU   61.71 (-3.38%)
F   12.89 (-2.86%)
CGC   2.84 (-3.07%)
GE   80.83 (-2.88%)
DIS   107.59 (-1.78%)
AMC   5.01 (-9.07%)
PFE   43.55 (-0.55%)
PYPL   79.64 (-2.68%)
NFLX   353.11 (-2.12%)
QQQ   290.27 (-2.02%)
AAPL   143.00 (-2.01%)
MSFT   242.71 (-2.20%)
META   147.06 (-3.08%)
GOOGL   96.94 (-2.45%)
AMZN   100.55 (-1.65%)
TSLA   166.66 (-6.32%)
NVDA   191.62 (-5.91%)
NIO   12.02 (-5.43%)
BABA   111.20 (-6.07%)
AMD   72.45 (-3.91%)
T   20.16 (+1.05%)
MU   61.71 (-3.38%)
F   12.89 (-2.86%)
CGC   2.84 (-3.07%)
GE   80.83 (-2.88%)
DIS   107.59 (-1.78%)
AMC   5.01 (-9.07%)
PFE   43.55 (-0.55%)
PYPL   79.64 (-2.68%)
NFLX   353.11 (-2.12%)
QQQ   290.27 (-2.02%)
AAPL   143.00 (-2.01%)
MSFT   242.71 (-2.20%)
META   147.06 (-3.08%)
GOOGL   96.94 (-2.45%)
AMZN   100.55 (-1.65%)
TSLA   166.66 (-6.32%)
NVDA   191.62 (-5.91%)
NIO   12.02 (-5.43%)
BABA   111.20 (-6.07%)
AMD   72.45 (-3.91%)
T   20.16 (+1.05%)
MU   61.71 (-3.38%)
F   12.89 (-2.86%)
CGC   2.84 (-3.07%)
GE   80.83 (-2.88%)
DIS   107.59 (-1.78%)
AMC   5.01 (-9.07%)
PFE   43.55 (-0.55%)
PYPL   79.64 (-2.68%)
NFLX   353.11 (-2.12%)
NASDAQ:CPRX

Catalyst Pharmaceuticals - CPRX Stock Forecast, Price & News

$15.72
+0.20 (+1.29%)
(As of 01/30/2023 04:31 PM ET)
Add
Compare
Today's Range
$15.31
▼
$16.10
50-Day Range
$14.76
▼
$21.05
52-Week Range
$5.51
▼
$22.11
Volume
2.34 million shs
Average Volume
3.41 million shs
Market Capitalization
$1.64 billion
P/E Ratio
25.77
Dividend Yield
N/A
Price Target
$20.38

Catalyst Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
29.6% Upside
$20.38 Price Target
Short Interest
Healthy
10.42% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.99
Upright™ Environmental Score
News Sentiment
0.75mentions of Catalyst Pharmaceuticals in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$14.87 M Sold Last Quarter
Proj. Earnings Growth
30.14%
From $0.73 to $0.95 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.98 out of 5 stars

Medical Sector

18th out of 1,049 stocks

Pharmaceutical Preparations Industry

7th out of 514 stocks

See Top Rated MarketRank™ Stocks Here

CPRX stock logo

About Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Receive CPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CPRX Stock News Headlines

January 25, 2023 | marketbeat.com
Pliant Therapeutics Gaps 34% Higher: More Upside To Come? (CPRX)
Pliant Therapeutics zoomed 34% higher and added to that gain in the next session.This followed good news about clinical trials for a lung-condition treatment.
January 11, 2023 | marketbeat.com
2 Biotechs Making Waves With A Single Product in their Pipeline (CPRX)
Catalyst Pharmaceuticals and Harmony Bioscience each have a single product in their respective pipelines, and both show incredible promise.
January 30, 2023 | Investing Trends (Ad)
"We need batteries. Literally everywhere."
Pretty much every technological megatrend today requires batteries. That includes EVs... 5G... AI... charging stations... and smart energy storage systems. Find out why the U.S. just added graphite to a list of super-critical minerals, calling it "essential for America's National Defense."
January 26, 2023 | finance.yahoo.com
Down 30% in a Day, Is Catalyst Pharmaceuticals Doomed?
January 25, 2023 | marketwatch.com
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day
January 25, 2023 | finanznachrichten.de
Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Completes the Acquisition of U.S. Rights to FYCOMPA (Perampanel) CIII
January 25, 2023 | msn.com
Here's How Much $1000 Invested In Catalyst Pharmaceuticals 15 Years Ago Would Be Worth Today
January 25, 2023 | finance.yahoo.com
Catalyst Pharmaceuticals Completes the Acquisition of U.S. Rights to FYCOMPA® (Perampanel) CIII
January 30, 2023 | Investing Trends (Ad)
Profit From the Commercial Solar Boom?
Solar energy had its best year ever in 2021, with a record 24 gigawatts of power installed. That's enough to power 18 million homes! Analysts expect the global solar farm market to reach $356 billion by 2028. The utility segment of the solar market is expected to grow at the highest annual growth rate in the industry, especially with the many tax incentives now offered.
January 25, 2023 | americanbankingnews.com
Catalyst Pharmaceuticals (NASDAQ:CPRX) Shares Gap Down to $20.80
January 24, 2023 | marketwatch.com
Catalyst Pharmaceuticals Inc. stock rises Tuesday, outperforms market
January 24, 2023 | msn.com
Catalyst (CPRX) Down on TEVA's FDA Filing for Firdapse Generic
January 23, 2023 | msn.com
Hot Stocks: EV stocks surge; W jumps on upgrade; PLRX soars on clinical data; CPRX plunges
January 23, 2023 | finanznachrichten.de
Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Notified of Abbreviated New Drug Application Filing for FIRDAPSE
January 23, 2023 | msn.com
$1000 Invested In This Stock 10 Years Ago Would Be Worth $27,000 Today
January 23, 2023 | finance.yahoo.com
Is Trending Stock Catalyst Pharmaceuticals, Inc. (CPRX) a Buy Now?
January 23, 2023 | finance.yahoo.com
3 Reasons Growth Investors Will Love Catalyst (CPRX)
January 23, 2023 | finance.yahoo.com
Catalyst Pharmaceuticals Comments on FDA's Announcement of its Position on Orphan Drug Exclusivity In Light of the 11th Circuit Decision in Catalyst Pharmaceuticals, Inc. v. Becerra
January 23, 2023 | finance.yahoo.com
Catalyst Pharmaceuticals Notified of Abbreviated New Drug Application Filing for FIRDAPSE®
January 20, 2023 | americanbankingnews.com
Catalyst Pharmaceuticals (NASDAQ:CPRX) Given New $22.00 Price Target at Truist Financial
January 19, 2023 | finance.yahoo.com
Catalyst Pharmaceutical (CPRX) Dips More Than Broader Markets: What You Should Know
January 19, 2023 | msn.com
Analyst Expectations for Catalyst Pharmaceuticals's Future
January 10, 2023 | finance.yahoo.com
Is Most-Watched Stock Catalyst Pharmaceuticals, Inc. (CPRX) Worth Betting on Now?
January 9, 2023 | finance.yahoo.com
Top Picks 2023- Catalyst Pharmaceutical CPRX
January 6, 2023 | finance.yahoo.com
Top Picks 2023- Catalyst Pharmaceuticals CPRX
December 21, 2022 | benzinga.com
HC Wainwright & Co. Maintains Buy Rating for Catalyst Pharmaceuticals: Here's What You Need To Know
December 19, 2022 | finance.yahoo.com
Catalyst Pharmaceuticals to Acquire U.S. Commercial Rights to FYCOMPA® (Perampanel) CIII From Eisai Co., Ltd
See More Headlines
Receive CPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CPRX Company Calendar

Last Earnings
11/09/2022
Today
1/30/2023
Next Earnings (Estimated)
3/15/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CPRX
CUSIP
N/A
CIK
1369568
Web
www.catalystpharma.com
Phone
(305) 420-3200
Fax
305-529-0933
Employees
76
Year Founded
2002

Price Target and Rating

Average Stock Price Forecast
$20.38
High Stock Price Forecast
$24.00
Low Stock Price Forecast
$15.50
Forecasted Upside/Downside
+29.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$0.61
Trailing P/E Ratio
25.77
Forward P/E Ratio
21.53
P/E Growth
N/A
Net Income
$39.48 million
Net Margins
34.90%
Pretax Margin
44.08%
Return on Equity
28.53%
Return on Assets
24.67%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.18
Quick Ratio
6.02

Sales & Book Value

Annual Sales
$191.76 million
Price / Sales
8.53
Cash Flow
$0.39 per share
Price / Cash Flow
40.04
Book Value
$2.01 per share
Price / Book
7.82

Miscellaneous

Outstanding Shares
104,071,000
Free Float
89,397,000
Market Cap
$1.64 billion
Optionable
Optionable
Beta
1.19

Social Links


Key Executives

  • Mr. Patrick J. McEnanyMr. Patrick J. McEnany (Age 76)
    Co-Founder, Chairman, Pres & CEO
    Comp: $1.05M
  • Ms. Alicia Grande C.M.A.Ms. Alicia Grande C.M.A. (Age 52)
    CPA, CMA, CPA, Chief Accounting Officer, VP, Treasurer & CFO
    Comp: $617.94k
  • Dr. Steven R. Miller Ph.D.Dr. Steven R. Miller Ph.D. (Age 61)
    COO & Chief Scientific Officer
    Comp: $745.71k
  • Dr. Gary Ingenito M.D.Dr. Gary Ingenito M.D. (Age 67)
    Ph.D., Chief Medical & Regulatory Officer
    Comp: $706.86k
  • Dr. Preethi Sundaram Ph.D. (Age 47)
    Chief Strategy Officer
    Comp: $511.25k
  • Ms. Mary Coleman
    VP & Head of Investor Relations
  • Mr. Brian Elsbernd J.D. (Age 59)
    Chief Compliance Officer & Chief Legal Officer
  • Mr. Pete Curry Sr.
    VP of Sales
  • Mr. Jeffrey Del Carmen (Age 52)
    Chief Commercial Officer
  • Mr. Philip B. Schwartz (Age 68)
    Corp. Sec.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













CPRX Stock - Frequently Asked Questions

Should I buy or sell Catalyst Pharmaceuticals stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CPRX shares.
View CPRX analyst ratings or view top-rated stocks.

What is Catalyst Pharmaceuticals' stock price forecast for 2023?

4 Wall Street research analysts have issued 12 month target prices for Catalyst Pharmaceuticals' stock. Their CPRX share price forecasts range from $15.50 to $24.00. On average, they expect the company's share price to reach $20.38 in the next year. This suggests a possible upside of 31.3% from the stock's current price.
View analysts price targets for CPRX or view top-rated stocks among Wall Street analysts.

How have CPRX shares performed in 2023?

Catalyst Pharmaceuticals' stock was trading at $18.60 at the beginning of 2023. Since then, CPRX stock has decreased by 16.6% and is now trading at $15.52.
View the best growth stocks for 2023 here.

When is Catalyst Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 15th 2023.
View our CPRX earnings forecast.

How were Catalyst Pharmaceuticals' earnings last quarter?

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) released its quarterly earnings results on Wednesday, November, 9th. The biopharmaceutical company reported $0.20 EPS for the quarter, topping analysts' consensus estimates of $0.19 by $0.01. The biopharmaceutical company had revenue of $57.24 million for the quarter, compared to the consensus estimate of $53.80 million. Catalyst Pharmaceuticals had a net margin of 34.90% and a trailing twelve-month return on equity of 28.53%.

What guidance has Catalyst Pharmaceuticals issued on next quarter's earnings?

Catalyst Pharmaceuticals issued an update on its FY 2022 earnings guidance on Friday, December, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $205.00 million-$210.00 million, compared to the consensus revenue estimate of $205.03 million.

What other stocks do shareholders of Catalyst Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Verastem (VSTM), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL) and TherapeuticsMD (TXMD).

What is Catalyst Pharmaceuticals' stock symbol?

Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX."

Who are Catalyst Pharmaceuticals' major shareholders?

Catalyst Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.40%), Artemis Investment Management LLP (0.25%), Cyndeo Wealth Partners LLC (0.10%), SummerHaven Investment Management LLC (0.10%), Yousif Capital Management LLC (0.07%) and State of Alaska Department of Revenue (0.06%). Insiders that own company stock include Alicia Grande, Charles B O'keeffe, David S Tierney, Donald A Denkhaus, Gary Ingenito, Patrick J Mcenany, Philip H Coelho, Preethi Sundaram and Steve Miller.
View institutional ownership trends.

How do I buy shares of Catalyst Pharmaceuticals?

Shares of CPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Catalyst Pharmaceuticals' stock price today?

One share of CPRX stock can currently be purchased for approximately $15.52.

How much money does Catalyst Pharmaceuticals make?

Catalyst Pharmaceuticals (NASDAQ:CPRX) has a market capitalization of $1.62 billion and generates $140.83 million in revenue each year. The biopharmaceutical company earns $39.48 million in net income (profit) each year or $0.61 on an earnings per share basis.

How can I contact Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The official website for the company is www.catalystpharma.com. The biopharmaceutical company can be reached via phone at (305) 420-3200, via email at bkorb@troutgroup.com, or via fax at 305-529-0933.

This page (NASDAQ:CPRX) was last updated on 1/30/2023 by MarketBeat.com Staff